SCHEMBL1450360

SCHEMBL1450360

O=C1C[CH]c2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CDC25B P30305 2/20 0.39
CES1 P23141 4/20 0.38
BCHE P06276 3/20 0.38
POLB P06746 3/20 0.38
IDO1 P14902 3/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 2/20 0.38
PTPRC P08575 2/20 0.38
MAPT P10636 2/20 0.38
THRB P10828 2/20 0.38
RECQL P46063 2/20 0.38
ALOX15 P16050 2/20 0.38
ALDH1A1 P00352 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
PTPN1 P18031 1/20 0.38
ACHE P22303 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29385734 0.76 CES1 (0.45) MEN1KMT2ACDC25BCES1BCHE
SCHEMBL249997 0.76 CES1 (0.45) MEN1KMT2ACDC25BCES1BCHE
SCHEMBL1148863 0.76 MAOA (0.43) MEN1KMT2ACDC25BCES1BCHE
SCHEMBL4455462 0.75 MAOA (0.48) MEN1KMT2ACDC25BCES1BCHE
SCHEMBL6487919 0.75 CES1 (0.43) MEN1KMT2ACDC25BCES1BCHE
Hydrochloric Acid SCHEMBL2710070 0.75 MEN1 (0.43) MEN1KMT2ACDC25BCES1BCHE
SCHEMBL30676949 0.75 CES1 (0.43) MEN1KMT2ACDC25BCES1BCHE
SCHEMBL30862184 0.75 CES1 (0.43) MEN1KMT2ACDC25BCES1BCHE
SCHEMBL7650600 0.73 MAOA (0.50) MEN1KMT2ACDC25BCES1BCHE
SCHEMBL3943765 0.73 MAOA (0.56) MEN1KMT2ACDC25BCES1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292241-A1 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2010-11-18 US claimed
EP-2244576-A1 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES Merck Sharp & Dohme Corp. (US) 2010-11-03 EP claimed
WO-2009094265-A1 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES MERCK & CO., INC. (US) 2009-07-30 WO claimed
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS GODEL THIERRY 2008-06-05 US claimed
EP-1689729-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. Hoffmann-La Roche AG (CH) 2006-08-16 EP claimed
WO-2005058857-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO claimed
US-20050119329-A1 Tetronic and tetramic acids HOFFMANN-LA ROCHE INC. 2005-06-02 US claimed
US-6743794-B2 MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE ELI LILLY AND COMPANY 2004-06-01 US claimed
US-6677452-B1 PREPARED BY REACTING AMINE WITH PYRIDINE SUBSTITUTED WITH HALOGEN AT POSITION 6 AND WITH CARBOXY OR SULFONYL GROUP AT ANOTHER POSITION TO FORM AMIDE OR SULFONAMIDE, DISPLACING HALOGEN WITH DESIRED DIAMINE LION BIOSCIENCE AG (DE) 2004-01-13 US claimed
EP-1218343-A4 PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2003-06-18 EP claimed
EP-1218343-A1 PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-07-03 EP claimed
WO-2001025203-A1 PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-04-12 WO claimed
CN-114716381-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-07-08 CN disclosed
CN-114634447-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-17 CN disclosed
CN-114621146-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-14 CN disclosed
CN-114605327-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-10 CN disclosed
US-6525070-B2 For therapy of chemokine (such as CCR3) or H1 mediated disease state ASTRAZENECA AB (SE) 2003-02-25 US disclosed
EP-1218343-A1 PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-07-03 EP disclosed
WO-2001025203-A1 PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-04-12 WO disclosed
EP-0757051-A1 PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME SUNTORY LIMITED (JP) 1997-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292241-A1 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES GRM2, GRM3, GRM1 MEN1 4634/4885KMT2A 1708/4885CDC25B 4400/4885
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS BACE1, PSEN1, BACE2 MEN1 1292/4885KMT2A 3781/4885CDC25B 3121/4885
US-20050119329-A1 Tetronic and tetramic acids BACE1, PSEN1, BACE2 MEN1 1292/4885KMT2A 3781/4885CDC25B 3121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.